Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Valiya, S
dc.contributor.author Bajorek, B
dc.date.accessioned 2012-02-02T11:01:28Z
dc.date.issued 2005-01
dc.identifier.citation Journal of Pharmacy Practice and Research, 2005, 35 (4), pp. 279 - 283
dc.identifier.issn 1445-937X
dc.identifier.other C1UNSUBMIT en_US
dc.identifier.uri http://hdl.handle.net/10453/15648
dc.description.abstract Background: The benefit of warfarin for stroke prevention in non-valvular atrial fibrillation has been demonstrated in various clinical trials. Warfarin has a nan'ow therapeutic window and carries a significant risk ofbleeding. Ximelagatran is a new oral antithrombotic with predictable plasma concentrations and excellent bioavailability. Aim: To compare the costs and benefits of ximelagatran to that of warfarin and aspirin. Method: In a preliminary cost-effectiveness analysis, the costs and clinical consequences ofwarf31in, aspirin and ximelagatran were compared. The principal outcome was measured in the fonn of an incremental cost-effectiveness ratio. A decision analysis model was constructed to map the expected outcomes of three treatment alternatives. Sensitivity analysis tested the robustness of the data.
dc.publisher Society of Hospital Pharmacists of Australia
dc.subject NA, Pharmacology & Pharmacy
dc.subject NA; Pharmacology & Pharmacy
dc.title Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation
dc.type Journal Article
dc.parent Journal of Pharmacy Practice and Research
dc.journal.volume 4
dc.journal.volume 35
dc.journal.number 4 en_US
dc.publocation Australia en_US
dc.identifier.startpage 279 en_US
dc.identifier.endpage 283 en_US
dc.cauo.name GSH.Pharmacy en_US
dc.conference Verified OK en_US
dc.for 1115 Pharmacology and Pharmaceutical Sciences
dc.personcode 0000069611 en_US
dc.personcode 112624 en_US
dc.percentage 100 en_US
dc.classification.name Pharmacology and Pharmaceutical Sciences en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords NA en_US
dc.description.keywords Limb rehabilitation, Backpropagation Neural Network, surface EMG (sEMG), Virtual Reality
dc.description.keywords NA
dc.staffid 112624 en_US
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Graduate School of Health
pubs.organisational-group /University of Technology Sydney/Strength - Health Services and Practice Research


Files in this item

This item appears in the following Collection(s)

Show simple item record